Paysign, Inc. Q3 FY25 Results

“Q3 2025 proved once again to be a record-breaking quarter for Paysign,” said Mark Newcomer, President and CEO. “Our revenue soared to $21.6 million, reflecting an outstanding 41.6% year-over-year growth rate. Adjusted EBITDA reached a new high of $5.0 million, up 78.1%, while net income improved by a healthy 54.2% to $2.2 million. These results underscore the exceptional momentum and improving operational efficiencies driving our business forward.” “Our pharma patient affordability business continues to exceed expectations, growing an impressive 141.9%. We ended the quarter with 105 active programs and anticipate adding another 20-30 programs before year end, a testament to the strong demand for our innovative solutions. During the quarter, we announced the opening of our new, 30,000-square-foot customer service contact center. This transformative expansion has increased our support capacity fourfold, empowering us to meet the surging demand and deliver exceptional service as we prepare for significant acceleration in our patient affordability business in the new year. With this enhanced infrastructure, we are fully prepared to capitalize on the tremendous growth opportunities ahead and continue setting new standards for excellence.” “Our plasma donor compensation business returned to year-over-year growth, increasing 12.4% over the prior year. Our suite of SaaS donor engagement technologies has been well received by plasma collection companies and plasmapheresis machine manufacturers alike. We continue to showcase these products to the plasma industry as we await FDA 510(k) approval on our donor management system targeted at the blood and plasma collection space.” “With patient affordability continuing its exceptional growth trajectory, growth returning to plasma, and the many opportunities that lie ahead for our SaaS engagement technology solutions, we are well-positioned to deliver long term value to our shareholders.”

“We delivered another quarter of solid operating results with our pharma patient affordability business leading the way, representing 36.7% of revenue, a significant increase from the 21.5% of revenue it contributed during the same period last year. This, coupled with the 117 net plasma centers we added over the past 12 months, continues to help offset the decline we continue to experience in plasma due largely to an industry-wide oversupply of plasma inventories which we expect will abate in the first half of 2026. Our gross profit margins improved by 70 basis points (bps) from 55.5% to 56.3%, due to a greater percentage of pharma patient affordability revenues, offset by the new plasma centers not being fully mature as well as additional costs associated with our new customer service contact center. Our operating margin improved by 280 bps from 4.5% to 7.3%, our net margin improved by 90 bps, from 9.4% to 10.3% and our Adjusted EBITDA margin improved by 480 bps, from 18.5% to 23.3%, demonstrating the operating leverage inherent in our business model while still making significant investments in people and infrastructure to ensure the success of our growing businesses,” said Jeff Baker, Paysign CFO. “With the results of our third quarter of 2025 now in the books, we are once again revising our full-year 2025 estimated results upward. In general, we expect our fourth quarter results to be similar to our third quarter results, reflecting flat plasma revenue, the launch of additional patient affordability programs and seasonally lower claim activity. Full-year 2025 total revenues are now estimated to be in the range of $80.5 million to $81.5 million, reflecting year-over-year growth of 38.7% at the midpoint. Plasma is estimated to make up approximately 57% of total revenue, reflecting modest year-over-year growth, while pharma patient affordability revenue is expected to make up approximately 41% of total revenue, representing year-over-year growth of over 155%. Full-year gross profit margins are expected to be approximately 60%. We expect operating expenses to be between $41.5 million and $42.5 million with depreciation and amortization expenses of approximately $8.4 million and stock-based compensation expense of approximately $4.3 million. Interest income is estimated to be approximately $2.6 million, reflecting lower interest rates and the implied interest expense for future Gamma payments. We expect our full-year tax rate to be 18.7% and our fully diluted share count to be 59.76 million shares. Taking all the factors above into consideration, we expect net income to be between $7.0 million and $8.0 million for the year, or $0.12 to $0.13 per diluted share. At the mid-point, this equates to a net margin of 9.3% versus 6.5% the year prior, an improvement of 280 basis points. Adjusted EBITDA is expected to be in the range of $19.0 million to $20.0 million, or $0.32 to $0.34 per diluted share. At the mid-point, this equates to an Adjusted EBITDA margin of 24.1% versus 16.5% the year prior, an improvement of 760 basis points,” Baker concluded.